HU218900B - Rekombináns vírusok génterápiai alkalmazásra szembetegségek kezelésére és ilyen vírusokat tartalmazó gyógyszerkészítmények - Google Patents

Rekombináns vírusok génterápiai alkalmazásra szembetegségek kezelésére és ilyen vírusokat tartalmazó gyógyszerkészítmények Download PDF

Info

Publication number
HU218900B
HU218900B HU9502573A HU9502573A HU218900B HU 218900 B HU218900 B HU 218900B HU 9502573 A HU9502573 A HU 9502573A HU 9502573 A HU9502573 A HU 9502573A HU 218900 B HU218900 B HU 218900B
Authority
HU
Hungary
Prior art keywords
adenovirus
gene
defective
defective recombinant
recombinant adenovirus
Prior art date
Application number
HU9502573A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9502573D0 (en
HUT73215A (en
Inventor
Pascale Briand
Michel Perricaudet
Original Assignee
Institut National de la Santé et de la Recherche Medicale (INSERM)
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Medicale (INSERM), Rhone-Poulenc Rorer S.A. filed Critical Institut National de la Santé et de la Recherche Medicale (INSERM)
Publication of HU9502573D0 publication Critical patent/HU9502573D0/hu
Publication of HUT73215A publication Critical patent/HUT73215A/hu
Publication of HU218900B publication Critical patent/HU218900B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
HU9502573A 1993-03-03 1994-02-28 Rekombináns vírusok génterápiai alkalmazásra szembetegségek kezelésére és ilyen vírusokat tartalmazó gyógyszerkészítmények HU218900B (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9302438A FR2702152B1 (fr) 1993-03-03 1993-03-03 Virus recombinants et leur utilisation en thérapie génique.

Publications (3)

Publication Number Publication Date
HU9502573D0 HU9502573D0 (en) 1995-10-30
HUT73215A HUT73215A (en) 1996-06-28
HU218900B true HU218900B (hu) 2000-12-28

Family

ID=9444602

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9502573A HU218900B (hu) 1993-03-03 1994-02-28 Rekombináns vírusok génterápiai alkalmazásra szembetegségek kezelésére és ilyen vírusokat tartalmazó gyógyszerkészítmények

Country Status (15)

Country Link
EP (1) EP0687184B1 (fr)
JP (1) JP3835809B2 (fr)
AT (1) ATE220923T1 (fr)
AU (1) AU693782B2 (fr)
CA (1) CA2154355A1 (fr)
DE (1) DE69431046T2 (fr)
DK (1) DK0687184T3 (fr)
ES (1) ES2181710T3 (fr)
FR (1) FR2702152B1 (fr)
HU (1) HU218900B (fr)
NO (1) NO319571B1 (fr)
NZ (1) NZ262135A (fr)
PT (1) PT687184E (fr)
WO (1) WO1994020146A1 (fr)
ZA (1) ZA941426B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
FR2726575B1 (fr) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa Virus recombinants, preparation et utilisation en therapie genique
FR2717823B1 (fr) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2718150B1 (fr) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
DE60022549T2 (de) * 1999-12-30 2006-05-18 Aventis Pharma S.A. Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
AU2004293474B2 (en) 2003-11-24 2010-12-23 Canji, Inc. Reduction of dermal scarring
ES2347340T3 (es) 2004-09-13 2010-10-28 Genzyme Corporation Construcciones multimericas.
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation VEGF antagonist compositions and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002551A2 (fr) * 1988-09-13 1990-03-22 Biosource Genetics Corporation Prophylaxie et traitement de maladies du systeme nerveux au moyen de melanine
AU655279B2 (en) * 1991-04-05 1994-12-15 Edison Animal Biotechnology Center Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences

Also Published As

Publication number Publication date
DK0687184T3 (da) 2002-10-28
FR2702152A1 (fr) 1994-09-09
FR2702152B1 (fr) 1995-05-24
ATE220923T1 (de) 2002-08-15
DE69431046D1 (de) 2002-08-29
NO953329L (no) 1995-08-24
WO1994020146A1 (fr) 1994-09-15
DE69431046T2 (de) 2003-02-13
ZA941426B (en) 1994-10-04
JP3835809B2 (ja) 2006-10-18
NO319571B1 (no) 2005-08-29
AU6144494A (en) 1994-09-26
EP0687184B1 (fr) 2002-07-24
NO953329D0 (no) 1995-08-24
HU9502573D0 (en) 1995-10-30
JPH08509208A (ja) 1996-10-01
AU693782B2 (en) 1998-07-09
EP0687184A1 (fr) 1995-12-20
NZ262135A (en) 2000-12-22
CA2154355A1 (fr) 1994-09-15
HUT73215A (en) 1996-06-28
ES2181710T3 (es) 2003-03-01
PT687184E (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
Hermens et al. Viral vectors, tools for gene transfer in the nervous system
CA2232985C (fr) Procedes de traitement de cancers et de la restenose a l'aide de p21
Li et al. In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector.
HU218900B (hu) Rekombináns vírusok génterápiai alkalmazásra szembetegségek kezelésére és ilyen vírusokat tartalmazó gyógyszerkészítmények
US7387614B2 (en) Drug delivery to the inner ear and methods of using same
Park et al. Stem cell-based delivery of brain-derived neurotrophic factor gene in the rat retina
Koeberle et al. Effects of adenoviral-mediated gene transfer of interleukin-10, interleukin-4, and transforming growth factor-β on the survival of axotomized retinal ganglion cells
Husseman et al. Gene therapy in the inner ear using adenovirus vectors
Spencer et al. Herpes simplex virus–mediated gene delivery to the rodent visual system
US20070264244A1 (en) Pigment epithelial cell of the eye, its production and use in therapy of an eye or CNS disease
JPH08506008A (ja) 心筋及び血管平滑筋へのアデノウィルス介在遺伝子移入
JPH10503361A (ja) 組換えｐ５３アデノウイルス方法と組成物
US6245330B1 (en) Recombinant adenoviruses coding for glial-derived neurotrophic factor (GDNF)
Weiss et al. Viral‐mediated gene transfer in the cochlea
HU229628B1 (en) Angiogenesis and vascular permeability modulators and inhibitors
Joung et al. Effective gene transfer into regenerating sciatic nerves by adenoviral vectors: potentials for gene therapy of peripheral nerve injury
ES2273521T5 (es) Terapia génica mediante adenovirus.
US20030086907A1 (en) Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases
US20020031493A1 (en) Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
Caleo et al. Expression of BCL‐2 via adeno‐associated virus vectors rescues thalamic neurons after visual cortex lesion in the adult rat
AU703793B2 (en) Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
US20080095835A1 (en) Methods for treating cancers and restenosis with P21
CN117500530A (zh) α-突触核蛋白抑制用组合物及聚集抑制方法
Doi et al. Bcl-2 expression mediated by Cre/loxP system in olfactory epithelium
Spencer A gene therapy approach for the treatment of retinal degeneration